It is concluded that EAM-2201 has the probable to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. In vitro results show that AM-2201 needs to be examined for possible pharmacokinetic drug interactions in vivo https://johny727gvi9.sharebyblog.com/profile